8.57

1.26% -0.17

Oric Pharmaceuticals Inc (ORIC)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$8.74

Offen:

$8.94

24-Stunden-Volumen:

27,611

Relative Volume:

0.06

Marktkapitalisierung:

$617.46M

Einnahmen:

Nettoeinkommen (Verlust:

$-100.70M

KGV:

-3.9312

EPS:

-2.18

Netto-Cashflow:

$-86.54M

1W Leistung:

-2.27%

1M Leistung:

-5.37%

6M Leistung:

-2.92%

1J Leistung:

+21.38%

1-Tages-Spanne:

$8.58

$9.00

1-Wochen-Bereich:

$8.105

$9.11

52-Wochen-Spanne:

$6.33

$16.65

Oric Pharmaceuticals Inc Stock (ORIC) Company Profile

Firmenname

Oric Pharmaceuticals Inc

Sektor

Healthcare (1195)

Branche

Biotechnology (683)

Telefon

(650) 388-5600

Adresse

240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA

Mitarbeiter

112

Twitter

Nächster Verdiensttermin

2024-11-04

Neueste SEC-Einreichungen

ORIC's Discussions on Twitter

Vergleichen Sie ORIC mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ORIC	8.58	617.46M	0	-100.70M	-86.54M	-2.18
VRTX	445.46	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	736.00	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	585.04	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	247.45	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	102.20	24.49B	3.30B	-501.07M	1.03B	11.54

Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2023-09-22	Eingeleitet	Wedbush	Outperform
2023-03-23	Hochstufung	H.C. Wainwright	Neutral → Buy
2023-03-21	Hochstufung	Guggenheim	Neutral → Buy
2023-03-16	Hochstufung	Oppenheimer	Perform → Outperform
2022-07-18	Fortgesetzt	Oppenheimer	Perform
2022-04-04	Hochstufung	Citigroup	Neutral → Buy
2022-03-25	Herabstufung	H.C. Wainwright	Buy → Neutral
2022-03-22	Herabstufung	Citigroup	Buy → Neutral
2022-03-22	Herabstufung	Guggenheim	Buy → Neutral
2022-03-22	Herabstufung	Oppenheimer	Outperform → Perform
2021-07-06	Hochstufung	Citigroup	Neutral → Buy
2021-01-25	Herabstufung	Citigroup	Buy → Neutral
2020-08-13	Eingeleitet	Robert W. Baird	Outperform
2020-08-06	Hochstufung	Citigroup	Neutral → Buy
2020-08-03	Eingeleitet	H.C. Wainwright	Buy
2020-05-19	Eingeleitet	Citigroup	Neutral
2020-05-19	Eingeleitet	Guggenheim	Buy
2020-05-19	Eingeleitet	JP Morgan	Overweight
2020-05-19	Eingeleitet	Jefferies	Buy

Alle ansehen

Oric Pharmaceuticals Inc Aktie (ORIC) Neueste Nachrichten

Nov 20, 2024

ORIC: Working with Two Pharma Giants, Analysts See +100% Upside - MSN

Nov 20, 2024

C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors - GlobeNewswire Inc.

Nov 20, 2024

Nov 18, 2024

ORIC Pharmaceuticals (NASDAQ:ORIC) Earns “Outperform” Rating from Wedbush - Defense World

Nov 14, 2024

Nov 13, 2024

Oric Pharmaceuticals Reports Strong Financial Growth and Clinical Progress - TipRanks

Nov 13, 2024

Alkeon Capital Management LLC's Strategic Acquisition in ORIC Ph - GuruFocus.com

Nov 13, 2024

Creative Planning Invests $116,000 in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World

Nov 13, 2024

FMR LLC Reduces Stake in ORIC Pharmaceuticals Inc - GuruFocus.com

Nov 13, 2024

Nov 12, 2024

ORIC Pharmaceuticals Inc Reports Q3 2024 Net Loss of $34.6 Milli - GuruFocus.com

Nov 12, 2024

ORIC Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 12, 2024

ORIC® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates - GlobeNewswire

Nov 12, 2024

ORIC Pharma Secures Major J&J, Bayer Partnerships; Reports $282M Cash Position | ORIC Stock News - StockTitan

Nov 12, 2024

Nov 08, 2024

ORIC Pharmaceuticals (NASDAQ:ORIC) Given “Buy” Rating at HC Wainwright - Defense World

Nov 08, 2024

Nov 06, 2024

ORICOric Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan

Nov 06, 2024

Nov 04, 2024

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - The Manila Times

Nov 04, 2024

Nov 03, 2024

Long Term Trading Analysis for (ORIC) - Stock Traders Daily

Nov 03, 2024

Nov 01, 2024

Wells Fargo Initiates Coverage of ORIC Pharmaceuticals (ORIC) with Overweight Recommendation - MSN

Nov 01, 2024

ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - StockTitan

Nov 01, 2024

Brokerages Set ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Price Target at $18.00 - Defense World

Nov 01, 2024

Oct 29, 2024

Dermavant acquisition expands Organon’s dermatology portfolio - Pharmaceutical Technology

Oct 29, 2024

Oct 23, 2024

ORIC-114 shows promise in preclinical cancer study By Investing.com - Investing.com Australia

Oct 23, 2024

ORIC-114 shows promise in preclinical cancer study - Investing.com

Oct 23, 2024

ORIC® Pharmaceuticals Presents Data Further Supporting Potential Best-In-Class Profile of ORIC-114 to Treat EGFR Exon 20 Insertions and Other Atypical Mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - GlobeNewswire

Oct 23, 2024

Oct 16, 2024

Analytical Overview: ORIC Pharmaceuticals Inc (ORIC)’s Ratios Tell a Financial Story - The Dwinnex

Oct 16, 2024